211 related articles for article (PubMed ID: 19335978)
1. [Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine].
Zhang L; Zhang DZ; Chen M; He H; Guo SH
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):175-9. PubMed ID: 19335978
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B.
Wang HJ; Jiang YF; Wang XR; Zhang ML; Gao PJ
World J Gastroenterol; 2016 May; 22(18):4529-37. PubMed ID: 27182162
[TBL] [Abstract][Full Text] [Related]
3. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
4. [Study on the correlation of the effect of entecavir on Th1/Th2 cytokines level in the treatment of chronic hepatitis].
Li L; Jing YB; Liu J; Wang CL; Liu B
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):606-611. PubMed ID: 29056011
[No Abstract] [Full Text] [Related]
5. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
7. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
8. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
9. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
[TBL] [Abstract][Full Text] [Related]
10. Th1/Th2 type cytokines in hepatitis B patients treated with interferon-alpha.
Xing T; Zhang L; Lu Q; Hou J; Feng X; Luo K
Chin Med J (Engl); 2001 Sep; 114(9):921-4. PubMed ID: 11780382
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
12. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
13. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
[TBL] [Abstract][Full Text] [Related]
14. [Predictor of effect of interferon-alpha on patients with hepatitis B: Th1/Th2 type cytokines].
Xing T; Zhang L; Lu Q
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):268-70. PubMed ID: 11798769
[TBL] [Abstract][Full Text] [Related]
15. Telbivudine for the management of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
18. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
Law ST; Lee MK; Li KK; Mok CK
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
[TBL] [Abstract][Full Text] [Related]
20. [The influences of camel milk on the immune response of chronic hepatitis B patients].
Saltanat H; Li H; Xu Y; Wang J; Liu F; Geng XH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 May; 25(5):431-3. PubMed ID: 19426601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]